<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161082</url>
  </required_header>
  <id_info>
    <org_study_id>R727-CL-1001</org_study_id>
    <nct_id>NCT01161082</nct_id>
  </id_info>
  <brief_title>Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending Single to Multi-Dose Study of Safety, Tolerability, and Bioeffect of Subcutaneously Administered REGN727 in Patients With and Without Concomitant Atorvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety, tolerability, and bioeffects (how the body reacts to the
      drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in
      hyperlipidemic patients with or without atorvastatin therapy. The study drug and placebo will
      be administered by subcutaneous injection at the clinic. There will be a total of 2 or 3
      study drug injections over 16 clinic visits, which will include 3 overnight stays(study
      duration 148 days, not including the screening period). Patients on atorvastatin will take
      their daily dose in the morning for the duration of the study. Patients will be monitored by
      the study staff for side effects and the body's response to the study drug. Vital signs(blood
      pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples
      will be collected at some or all visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in hyperlipidemic patients treated with REGN727 or placebo receiving stable doses of atorvastatin.</measure>
    <time_frame>visit 4 (day 1) to visit 16 (day 148)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacodynamic effect of REGN727 added to atorvastatin on lipids</measure>
    <time_frame>Visit 4 (Day 1) to Visit 16 (Day 148)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacodynamic effect of monotherapy REGN727 in hyperlipidemic patients</measure>
    <time_frame>Visit 4 (Day 1) to Visit 16 (Day 148)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetics of REGN727 in hyperlipidemic patients with or without atorvastatin</measure>
    <time_frame>Visit 4 (Day 1) to Visit 16 (Day 148)</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Group 1 with atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 with atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 with atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 with atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5 with atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6 with atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7 without atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8 with atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose4 versus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN727(SAR236553)</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>Group 1 with atorvastatin</arm_group_label>
    <arm_group_label>Group 2 with atorvastatin</arm_group_label>
    <arm_group_label>Group 3 with atorvastatin</arm_group_label>
    <arm_group_label>Group 4 with atorvastatin</arm_group_label>
    <arm_group_label>Group 5 with atorvastatin</arm_group_label>
    <arm_group_label>Group 6 with atorvastatin</arm_group_label>
    <arm_group_label>Group 7 without atorvastatin</arm_group_label>
    <arm_group_label>Group 8 with atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Men and women with elevated cholesterol on stable doses of atorvastatin 10-40mg/day
             regimen

          -  Body mass index between 18.0 and 35.0 kg/m2, inclusive

          -  For women of childbearing potential, a negative serum pregnancy test at the screening
             visit and a negative urine pregnancy test on day -2 or day -1

          -  For men and women of childbearing potential, willingness to utilize adequate
             contraception and not become pregnant (or have their partner[s] become pregnant)during
             the full duration of the study

          -  Willing, committed and able to return for all the clinic visits and complete all
             study-related procedures

          -  Able to read, and able to sign the informed consent form

        Exclusion Criteria:

          -  History of MI, ACS, Angina, Stroke, peripheral vascular disease, or cardiac
             revascularization

          -  Pregnant or breast-feeding women

          -  Blood donation of any volume within 1 month prior to administration of study drug

          -  Congestive heart failure

          -  Consumption of greater than 1 quart of grapefruit juice per day

          -  Previous exposure to any therapeutic or investigational biological agent within 30
             days of screening

          -  History of alcohol or drug abuse within one year to the screening visit

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Swergold, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>January 24, 2015</last_update_submitted>
  <last_update_submitted_qc>January 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

